C4 Therapeutics (CCCC) Short Interest Ratio & Short Volume $1.64 +0.06 (+3.80%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock C4 Therapeutics Short Interest DataC4 Therapeutics (CCCC) has a short interest of 7.73 million shares, representing 11.97% of the float (the number of shares available for trading by the public). This marks a -0.39% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.6, indicating that it would take 5.6 days of the average trading volume of 1.41 million shares to cover all short positions.Current Short Interest7,730,000 sharesPrevious Short Interest7,760,000 sharesChange Vs. Previous Month-0.39%Dollar Volume Sold Short$9.20 millionShort Interest Ratio5.6 Days to CoverLast Record DateApril 15, 2025Outstanding Shares71,007,000 sharesShort Percent of Float11.97%Today's Trading Volume509,343 sharesAverage Trading Volume1,409,553 sharesToday's Volume Vs. Average36% Short Selling C4 Therapeutics? Sign up to receive the latest short interest report for C4 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCCCC Short Interest Over TimeCCCC Days to Cover Over TimeCCCC Percentage of Float Shorted Over Time C4 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20257,730,000 shares $9.20 million -0.4%12.0%5.6 $1.19 3/31/20257,760,000 shares $12.42 million -5.0%12.0%5.4 $1.60 3/15/20258,170,000 shares $16.59 million -4.4%12.7%5 $2.03 2/28/20258,550,000 shares $23.17 million +6.1%13.2%4.7 $2.71 2/15/20258,060,000 shares $25.63 million +8.9%12.5%4.4 $3.18 1/31/20257,400,000 shares $25.68 million -20.3%N/A4.4 $3.47 1/15/20259,280,000 shares $37.49 million +7.9%N/A6 $4.04 12/31/20248,600,000 shares $30.96 million -3.0%N/A6.4 $3.60 12/15/20248,870,000 shares $38.85 million +11.0%N/A7.3 $4.38 11/30/20247,990,000 shares $36.35 million +8.0%N/A7.3 $4.55 Get the Latest News and Ratings for CCCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20247,400,000 shares $31.89 million +26.5%N/A7.3 $4.31 10/31/20245,850,000 shares $31.18 million -12.0%N/A6 $5.33 10/15/20246,650,000 shares $41.90 million -39.6%N/A6.7 $6.30 9/30/202411,010,000 shares $62.76 million -7.6%N/A9 $5.70 9/15/202411,920,000 shares $76.76 million +2.5%N/A8.1 $6.44 8/31/202411,630,000 shares $73.50 million +10.8%N/A7.4 $6.32 8/15/202410,500,000 shares $61.53 million +0.3%N/A6.6 $5.86 7/31/202410,470,000 shares $70.15 million -10.0%N/A6.3 $6.70 7/15/202411,630,000 shares $75.48 million +32.0%N/A7 $6.49 6/30/20248,810,000 shares $40.70 million -39.4%N/A5.7 $4.62 6/15/202414,540,000 shares $63.69 million +9.7%N/A10.2 $4.38 5/31/202413,260,000 shares $66.30 million +16.9%N/A8.4 $5.00 5/15/202411,340,000 shares $69.29 million +11.8%N/A5.9 $6.11 4/30/202410,140,000 shares $63.88 million +6.1%N/A4.5 $6.30 4/15/20249,560,000 shares $65.58 million +4.5%N/A3.7 $6.86 3/31/20249,150,000 shares $74.76 million +73.0%N/A2.4 $8.17 3/15/20245,290,000 shares $47.24 million +78.1%N/A1.1 $8.93 2/29/20242,970,000 shares $32.61 million -6.6%N/A0.2 $10.98 2/15/20243,180,000 shares $25.12 million -5.1%N/A0.2 $7.90 1/31/20243,350,000 shares $20.70 million -39.6%8.7%0.2 $6.18 1/15/20245,550,000 shares $37.74 million +22.3%14.5%0.4 $6.80 12/31/20234,540,000 shares $25.65 million -44.0%10.8%0.3 $5.65 12/15/20238,100,000 shares $40.10 million +330.9%19.3%0.7 $4.95 11/30/20231,880,000 shares $3.06 million -3.6%4.5%3.4 $1.63 11/15/20231,950,000 shares $3.51 million +2.1%4.7%4.1 $1.80 10/31/20231,910,000 shares $2.85 million +4.4%4.6%3.9 $1.49 10/15/20231,830,000 shares $3.64 million -19.0%4.6%3.8 $1.99 9/30/20232,260,000 shares $4.20 million -5.0%5.6%5.2 $1.86 9/15/20232,380,000 shares $5.31 million +14.4%5.9%2.4 $2.23 8/31/20232,080,000 shares $6.03 million +9.5%5.2%1.9 $2.90Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 8/15/20231,900,000 shares $6.42 million -10.0%4.7%1.6 $3.38 7/31/20232,110,000 shares $8.21 million -5.8%5.3%1.7 $3.89 7/15/20232,240,000 shares $7.50 million -8.9%5.6%1.8 $3.35 6/30/20232,460,000 shares $6.77 million -26.4%6.1%2 $2.75 6/15/20233,340,000 shares $12.06 million +2.8%8.3%5.1 $3.61 5/31/20233,250,000 shares $11.02 million +12.1%8.1%5.4 $3.39 5/15/20232,900,000 shares $9.69 million +0.7%7.2%5.2 $3.34 4/30/20232,880,000 shares $8.70 million +1.8%7.0%5 $3.02 4/15/20232,830,000 shares $9.48 million +7.6%6.9%4.9 $3.35 3/31/20232,630,000 shares $8.26 million -9.9%6.5%4.5 $3.14 3/15/20232,920,000 shares $12.59 million -10.2%7.2%5.1 $4.31 2/28/20233,250,000 shares $17.13 million +0.9%8.0%6.3 $5.27 2/15/20233,220,000 shares $18.58 million -12.5%7.9%6.1 $5.77 1/31/20233,680,000 shares $28.67 million +2.8%9.0%7 $7.79 1/15/20233,580,000 shares $30.57 million +2.0%8.8%7.8 $8.54 12/30/20223,510,000 shares $20.71 million -3.6%8.6%7.8 $5.90 12/15/20223,640,000 shares $29.48 million +0.3%8.9%8 $8.10 11/30/20223,630,000 shares $31.11 million -8.1%8.9%7.5 $8.57 11/15/20223,950,000 shares $38.39 million -19.1%9.7%8.5 $9.72 10/31/20224,880,000 shares $46.95 million -1.2%11.9%11.4 $9.62 10/15/20224,940,000 shares $39.32 million -2.0%12.9%12.1 $7.96 9/30/20225,040,000 shares $44.20 million +11.0%13.2%11.9 $8.77 9/15/20224,540,000 shares $51.57 million -6.8%11.8%9.8 $11.36 8/31/20224,870,000 shares $49.09 million -5.1%12.7%9.9 $10.08 8/15/20225,130,000 shares $62.23 million -3.2%13.4%9.2 $12.13 7/31/20225,300,000 shares $51.09 million +1.5%13.9%8.2 $9.64 7/15/20225,220,000 shares $52.30 million +2.8%13.7%7.2 $10.02 6/30/20225,080,000 shares $38.30 million +20.7%13.3%4.7 $7.54 6/15/20224,210,000 shares $23.11 million -2.1%11.0%3.7 $5.49 5/31/20224,300,000 shares $31.22 million +10.3%11.3%4.2 $7.26 5/15/20223,900,000 shares $27.89 million -23.7%10.2%3.9 $7.15 4/30/20225,110,000 shares $43.79 million -4.7%13.4%5.4 $8.57 4/15/20225,360,000 shares $47.97 million +4.7%14.0%5.8 $8.95 3/31/20225,120,000 shares $124.21 million +8.5%13.4%7.2 $24.26 3/15/20224,720,000 shares $101.48 million +29.7%12.4%9.8 $21.50 2/28/20223,640,000 shares $81.65 million +8.7%9.5%7.6 $22.43 2/15/20223,350,000 shares $80.03 million +23.2%8.8%7.7 $23.89 1/31/20222,720,000 shares $66.45 million -13.1%7.1%6.7 $24.43 1/15/20223,130,000 shares $86.20 million -1.6%8.1%9.5 $27.54 12/31/20213,180,000 shares $102.40 million +6.0%8.3%10.9 $32.20 12/15/20213,000,000 shares $91.50 million +8.3%7.8%11 $30.50 11/30/20212,770,000 shares $102.82 million +0.4%7.2%10.6 $37.12 11/15/20212,760,000 shares $115.09 million +2.2%7.2%10.3 $41.70 10/29/20212,700,000 shares $119.93 million +1.5%7.0%9.9 $44.42 10/15/20212,660,000 shares $116.75 million No Change6.9%8.7 $43.89 9/30/20212,660,000 shares $118.85 million +17.2%6.9%7.9 $44.68 9/15/20212,270,000 shares $110.75 million -6.2%5.9%5.7 $48.79 8/31/20212,420,000 shares $97.11 million -11.7%6.6%5.5 $40.13 8/13/20212,740,000 shares $107.82 million +3.4%7.4%6 $39.35 7/30/20212,650,000 shares $114.32 million No Change8.1%5.5 $43.14Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 7/15/20212,650,000 shares $98.90 million -5.0%8.1%5.8 $37.32 6/30/20212,790,000 shares $105.57 million +18.2%8.5%6 $37.84 6/15/20212,360,000 shares $88.88 million -3.7%7.2%5.5 $37.66 5/28/20212,450,000 shares $90.53 million -7.9%7.4%6.4 $36.95 5/14/20212,660,000 shares $90.60 million +1.9%8.0%7.7 $34.06 4/30/20212,610,000 shares $89.37 million -12.1%7.9%8.6 $34.24 4/15/20212,970,000 shares $98.54 million -19.1%9.0%10.3 $33.18 3/31/20213,670,000 shares $120.74 million +77.3%11.1%13.8 $32.90 3/15/20212,070,000 shares $92.40 million +6.7%6.4%8 $44.64 2/26/20211,940,000 shares $81.00 million +21.3%5.9%7.7 $41.75 2/12/20211,600,000 shares $72.86 million +3.9%4.8%5.5 $45.54 1/29/20211,540,000 shares $55.70 million -14.9%4.4%3.9 $36.17 1/15/20211,810,000 shares $68.73 million No Change5.2%3.8 $37.97 CCCC Short Interest - Frequently Asked Questions What is C4 Therapeutics' current short interest? Short interest is the volume of C4 Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 7,730,000 shares of CCCC short. 11.97% of C4 Therapeutics' shares are currently sold short. Learn More on C4 Therapeutics' current short interest. What is a good short interest ratio for C4 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CCCC shares currently have a short interest ratio of 6.0. Learn More on C4 Therapeutics's short interest ratio. Which institutional investors are shorting C4 Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of C4 Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for C4 Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.97% of C4 Therapeutics' floating shares are currently sold short. Is C4 Therapeutics' short interest increasing or decreasing? C4 Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 7,730,000 shares, a decline of 0.4% from the previous total of 7,760,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does C4 Therapeutics' short interest compare to its competitors? 11.97% of C4 Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to C4 Therapeutics: ABIVAX Société Anonyme (2.83%), Autolus Therapeutics plc (5.79%), Eton Pharmaceuticals, Inc. (1.82%), Revance Therapeutics, Inc. (4.32%), Rapport Therapeutics (14.01%), Amylyx Pharmaceuticals, Inc. (6.50%), Zevra Therapeutics, Inc. (10.94%), Mereo BioPharma Group plc (4.44%), Altimmune, Inc. (32.90%), Kamada Ltd. (0.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short C4 Therapeutics stock? Short selling CCCC is an investing strategy that aims to generate trading profit from C4 Therapeutics as its price is falling. CCCC shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against C4 Therapeutics? A short squeeze for C4 Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CCCC, which in turn drives the price of the stock up even further. How often is C4 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CCCC, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies ABVX Short Interest AUTL Short Interest ETON Short Interest RVNC Short Interest RAPP Short Interest AMLX Short Interest ZVRA Short Interest MREO Short Interest ALT Short Interest KMDA Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CCCC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CCCC Stock Free CCCC Stock Alerts